Multiple-variable IL-2 Dose Regimen for GVHD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for graft-versus-host disease (GVHD) are inadequate in maintaining long-term inflammatory control and often fail to effectively enhance the function of adoptively transferred regulatory T-cells (Tregs), particularly in pediatric patients, who suffer from debilitating consequences such as sclerotic skin and pulmonary fibrosis.
Innovation Solution
A multiple-variable dose regimen of Interleukin-2 (IL-2) is administered to pediatric patients, first as an induction regimen to increase the ratio of regulatory T lymphocytes (Tregs) to conventional T lymphocytes (Tcons), followed by a maintenance regimen with a higher dose to further enhance Treg numbers and activity, potentially combined with additional therapies like ECP or Treg infusions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If low-dose IL-2 is administered to enhance Tregs, then Treg function is improved, but clinical benefit is obtained in only half of patients
Solution Approach 1:
The patent implements dynamic dosing by transitioning from a fixed low-dose IL-2 regimen to a multi-phase protocol where the dose is adjusted based on patient response and Treg:Tcon ratio measurements. The induction phase uses higher doses to rapidly expand Tregs, followed by maintenance phases with adjusted doses to sustain therapeutic effect, thereby improving reliability while reducing response variability.
Solution Approach 2:
The patent incorporates feedback mechanisms by monitoring Treg:Tcon ratios and clinical response to adjust IL-2 dosing. Phase 1 establishes baseline Treg expansion, phase 2 adjusts dosing based on achieved ratios, and phase 3 maintains therapy based on sustained response, creating a closed-loop system that improves clinical benefit rate and reduces variability.
2Reliability
If ex vivo expanded Tregs are infused to control immune activation, then immune tolerance is improved, but long-term function maintenance is difficult to achieve
Solution Approach 1:
The patent applies preliminary action by using the induction phase to pre-expand and activate Tregs before they need to provide long-term control. The high-dose IL-2 in phase 1 creates a robust Treg pool that can then be maintained at lower doses in phases 2 and 3, ensuring long-term function is established before maintenance begins.
Solution Approach 2:
The patent ensures continuity of useful action by implementing a multi-phase continuous IL-2 therapy protocol. Rather than a single infusion, the treatment continues through induction, consolidation, and maintenance phases with ongoing IL-2 administration that sustains Treg function and prevents decay over time, thereby achieving long-term immune control.
3Reliability
If a single fixed dose of IL-2 is used to treat GVHD, then treatment simplicity is maintained, but inadequate clinical response is observed in many patients
Solution Approach 1:
The patent segments the treatment into distinct phases (induction, consolidation, maintenance) with different dosing strategies. Phase 1 uses higher doses for rapid Treg expansion, phase 2 adjusts based on response, and phase 3 maintains therapy. This segmentation improves clinical response by addressing different therapeutic needs at different time points while organizing complexity into manageable stages.
Solution Approach 2:
The patent changes dosing parameters over time and based on patient response. The IL-2 dose is adjusted between phases and within phases based on Treg:Tcon ratios and clinical status. This dynamic parameter adjustment improves clinical response rate by optimizing the balance between efficacy and toxicity for each patient, while the structured approach manages the inherent complexity.
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
The present invention is based, in part, on the identification of iiicihods of using multiple-variable IL-2 doses for identifying, assessing, preventing, and treating immune disorders.